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ABSTRACT
Objectives. The national Viral Hepatitis Action Plan recommends strengthening 
partnerships among health departments, community-based organizations, and 
health-care providers for hepatitis services. We implemented a hepatitis C virus 
(HCV) testing and linkage-to-care program through a local health department 
using similar strategies reported for HIV care. 
Methods. The Durham County Department of Public Health received federal 
funding to conduct HCV testing and linkage to care in Durham, North Caro-
lina. HCV antibody testing with reflex RNA was offered through a sexually 
transmitted disease clinic, a county jail, community testing sites (including 
a residential substance abuse recovery program), and a homeless clinic. 
People with evidence of HCV infection were linked to care through an HCV 
bridge counselor who provided education, incentives, and transportation, and 
scheduled appointments with HCV specialists at nearby academic centers and 
on-site clinics.
Results. From December 2012 through February 2014, we conducted 2,004 
HCV tests, of which 326 (16.3%) were HCV antibody positive and 241 (12.0%) 
had detectable HCV RNA. Among the 241 people with HCV infection, 178 
(73.9%) were men, and 133 (55.2%) were born between 1945 and 1965. Of 241 
people with chronic HCV infection, 150 (62.2%) reported ever injecting drugs, 
eight (2.5%) were coinfected with HIV, and 123 (51.0%) were linked to care. 
Conclusion. At the local public health level, HCV testing and linkage to care 
can be facilitated with additional funding and by leveraging existing programs 
and provider networks to deliver a coordinated system of care. 
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Advances have been made in the treatment of hepa-
titis C virus (HCV) infection with the introduction of 
direct-acting antiviral therapies in the United States. 
However, only 38% of the estimated 3 million people 
living with HCV infection in this country have been 
linked to care, 11% have been treated, and 6% have 
achieved cure based on data prior to the new era of 
interferon-free treatment.1 In 2011, the U.S. Depart-
ment of Health and Human Services released the Viral 
Hepatitis Action Plan to combat viral hepatitis.2 One 
of its key strategies was to launch and strengthen part-
nerships among local health departments, community-
based organizations, and health-care providers for 
HCV services, especially for intravenous drug users 
(IDUs). Fortunately, many public health departments 
are already positioned within established community 
networks that can be leveraged to raise awareness, 
increase education, and facilitate HCV testing and 
linkage to care for vulnerable populations. 
North Carolina has one of the fastest-growing 
populations in the southeastern United States and has 
faced challenges with the provision of health care for 
the uninsured, including screening and treatment for 
HCV. Prior to 2012, HCV screening was not routinely 
offered through North Carolina health departments. 
A handful of programs were providing HCV antibody 
(anti-HCV) testing but not confirmatory HCV ribo-
nucleic acid (RNA) assays because of cost. Only acute 
HCV infections are reportable in North Carolina, and 
no surveillance for chronic HCV infection exists. From 
2008 to 2012, North Carolina reported an average of 
46 acute HCV infections per year;3 however, this num-
ber was likely an underestimation of the total burden. 
Extrapolation of the numbers of acute HCV infection 
suggests that the number of chronic HCV infections 
in North Carolina is much higher than estimated.4
In December 2012, the Durham County Department 
of Public Health initiated a program for HCV testing 
and linkage to care funded by federal Prevention and 
Public Health Funds. Durham County is the sixth-
largest county in North Carolina and has experienced 
high rates of human immunodeficiency virus (HIV) 
infection and syphilis potentially associated with social 
determinants of health, including poverty and access 
to health care.5 Kolman et al. previously identified 
barriers to testing and treatment for HIV infection, 
sexually transmitted diseases (STDs), and viral hepa-
titis in Durham as cost, lack of transportation, and 
stigma associated with a diagnosis.6 To address these 
barriers, we implemented strategies to integrate HCV 
testing into existing HIV testing programs for at-risk 
populations and to facilitate HCV linkage to care with 
health-care providers in the community. We describe 
our activities and lessons learned from the implementa-
tion process and summarize our outcomes data from 
the project’s first year. 
METHODS
Upon notification of a Prevention and Public Health 
Fund grant from the Centers for Disease Control and 
Prevention (CDC), project staff members at the Dur-
ham County Department of Public Health convened 
several meetings with key community partners and 
health-care providers who had an interest in expanding 
HCV testing and care. Based on CDC recommendations 
for HCV testing,7 we primarily targeted HCV testing 
efforts toward current and past IDUs, HIV-infected 
individuals, and people born between 1945 and 1965, 
or baby boomers (for one-time testing). We also con-
sidered other risk factors for HCV infection, including 
incarceration, long-term sexual exposure to an HCV-
infected person, history of multiple sexual partners or 
STDs, or men who have sex with men. 
To maximize access to the at-risk groups, we coor-
dinated HCV testing through the local health depart-
ment in the STD clinic, the county jail, community 
testing sites (including a residential substance abuse 
recovery program), and a clinic providing health care 
for the homeless. We drafted policies and procedures 
for internal programs (i.e., STD clinic, county jail, 
and community testing program), and we developed 
a memorandum of understanding with external orga-
nizations (i.e., the substance abuse recovery program, 
homeless clinic, and academic hospitals) prior to 
implementation of activities that included HCV refer-
rals, on-site clinics, and sharing of confidential patient 
information for disease reporting and linkage services.
HCV testing process
Clinicians and health educators offered HCV testing 
along with HIV and STD screening in the STD clinic 
and at the community testing sites already providing 
these services. Testing was typically conducted on-site at 
the testing locations or in a mobile van during some of 
the community testing events. The county jail offered 
universal opt-out testing for HCV among inmates, while 
other locations offered targeted HCV testing based on 
predetermined risk factors. Risk-factor information was 
collected using a standard collection form from each 
testing site. Schoenbachler et al. describe additional 
information regarding the HCV testing process at the 
Durham County jail.8
We conducted anti-HCV testing with reflex HCV RNA 
testing for positive results through a memorandum of 
understanding with the University of North Carolina 
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Hospital laboratory. Two blood specimens collected 
from individuals at the testing sites were processed and 
transported to the University of North Carolina by the 
next business day. The anti-HCV test was based on a 
chemiluminescent microparticle immunoassay (Abbott 
ARCHITECT® Anti-HCV, Abbott Laboratories, Abbott 
Park, Illinois), and the quantitative HCV RNA was 
conducted using polymerase chain reaction (Abbott 
RealTime HCV Assay, Abbott Laboratories). We also 
offered rapid anti-HCV testing (OraQuick® HCV Test, 
OraSure Technologies, Bethlehem, Pennsylvania) to 
some individuals in the community, especially when 
we deemed it important to have immediate results for 
the population being tested (e.g., those at bus stops or 
housing complexes). If the rapid test was positive, we 
attempted to confirm all positive rapid HCV tests with 
quantitative HCV RNA assays by collecting additional 
blood specimens on the same day.
HCV pretest and posttest counseling 
Health educators and project staff members provided 
HCV-specific information and prevention messages 
according to CDC guidelines7 using written materi-
als in English or Spanish during individual or group 
counseling sessions at each site. People tested at the 
STD or homeless clinic were asked to return in two 
weeks for results. People with evidence of HCV infec-
tion tested at the county jail were given their results as 
soon as possible, while residents at the substance abuse 
recovery program were given monthly test results to 
minimize interruptions with work requirements during 
the two-year program. Individuals who tested positive 
for anti-HCV, with or without detectable HCV RNA, 
were counseled and referred for hepatitis A/B vaccina-
tion at the health department. Trained staff members 
used CDC guidelines to provide posttest counseling 
for people with chronic HCV infection, including the 
need for preventing further harm to their liver, reduc-
ing risks of transmitting HCV to others, and medical 
evaluation for chronic liver disease and treatment.7 
HCV linkage to care
Consistent with definitions from the HIV care con-
tinuum,9 we defined HCV linkage to care as the pro-
cess of assisting people diagnosed with chronic HCV 
infection with their initial visits with an HCV medical 
provider. Similar to strategies for people with newly 
diagnosed HIV infection,10–12 we used an HCV bridge 
counselor or patient navigator to assist with posttest 
counseling and active linkage to care for people with 
chronic HCV infection. The bridge counselor had a 
health education background and received additional 
training from HIV disease intervention specialists who 
had experience working with the community. Upon 
confirmation of the diagnosis, the bridge counselor 
either met with or called individuals to facilitate link-
age to care. Attempts to contact people identified with 
HCV infection involved at least two telephone calls and 
letters; bridge counselors also conducted home visits to 
locate individuals in the community as needed. During 
the bridging session, the counselor reviewed medical 
and drug history with each client, and provided HCV 
education, alcohol- and drug-reduction counseling, 
and HCV control measures as per North Carolina 
communicable disease laws.13
The counselor initially provided options for linkage 
to care at either a liver specialist located at Duke Univer-
sity (Durham) or to infectious disease physicians at the 
University of North Carolina (Chapel Hill), who could 
provide HCV care to patients regardless of insurance 
status. In the latter half of the project period, these spe-
cialists began providing on-site assessments for people 
with chronic HCV infection at the residential substance 
abuse recovery program and the health department to 
reduce individual barriers to care. The HCV bridge 
counselor assisted with scheduling appointments and 
sent reminders after the bridging sessions. Gift cards 
($10) or bus passes were also provided to people with 
chronic HCV infection as incentives to attend their first 
appointments. People diagnosed with chronic HCV 
infection while in jail were contacted and linked to 
care after release; when possible, detainees not released 
were referred for further care to the North Carolina 
Department of Corrections. 
HCV data entry and analysis
We entered data from the standardized collection 
forms into EvaluationWeb®, an Internet-based data 
collection system14 that CDC provided to grantees. 
We downloaded demographic, HCV risk-factor, HCV 
test-result, and linkage-to-care data from this database 
for people tested from December 10, 2012, to Febru-
ary 20, 2014. We calculated the prevalence of chronic 
HCV infection, based on a positive anti-HCV test and 
detectable HCV RNA level, overall and for each testing 
site. We also examined the distribution of demographic 
characteristics and HCV risk factors for people with and 
without a positive anti-HCV test and for people with 
chronic HCV infection. We focused on age, sex, race/
ethnicity, country of birth, and health insurance status. 
We evaluated injection drug use history (i.e., ever and 
within the past 12 months), HIV infection status, and 
birth year as the primary HCV risk factors of interest. 
All analyses were performed using SAS® version 9.2.15 
Health department staff members also entered 
individual-level data regarding people identified with 
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chronic HCV infection into the North Carolina Elec-
tronic Disease Surveillance System.16 However, the state 
did not monitor these cases for surveillance purposes 
because only acute HCV infections are reportable in 
North Carolina. 
RESULTS
We conducted 2,004 anti-HCV tests from all testing 
sites, of which 326 (16.3%) were positive and under-
went reflex RNA testing and 241 (12.0%) had detect-
able HCV RNA levels. The prevalence of chronic HCV 
infection among people tested was 10.0% (47/471) 
at the STD clinic, 9.3% (66/708) at the county jail, 
14.7% (109/741) at community testing sites, and 
22.6% (19/84) at the homeless clinic (Table 1). 
Among all 2,004 people tested, the median age was 37 
years (interquartile range [IQR] 5 27–50), and 609 
(30.4%) people tested were born between 1945 and 
1965. Most participants were male (n51,456, 72.7%), 
black (n51,255, 62.6%), and uninsured (n51,349, 
67.3%) (Table 2). 
Among the 241 people identified with chronic HCV 
infection, the median age was 49 years (IQR535–55), 
178 (73.9%) were male, 123 (51.0%) self-identified as 
black, 107 (44.4%) self-identified as white, and three 
(1.2%) self-identified as Hispanic. The percentage 
of people with chronic HCV infection in the birth 
cohort was 55% (133/241), and six of 241 (2.5%) 
HCV-infected people had self-reported HIV coinfec-
tion. Most of the 241 individuals diagnosed with 
chronic HCV infection reported a history of having 
ever injected drugs (n5150, 62.2%), of whom 65 
(43.3%) reported that they had injected drugs in the 
past 12 months.
Of the 241 people identified with chronic HCV infec-
tion through all testing sites, 197 (81.7%) received their 
HCV results and posttest counseling and 44 (18.3%) 
could not be contacted despite telephone calls, let-
ters, or a home visit by the HCV bridge counselor. Of 
the 197 people who received posttest counseling, 134 
(68.0%) were referred to care, of whom 123 (91.8%) 
attended their first appointment with an HCV care 
provider. Of 197 people identified with chronic HCV 
infection, 54 (27.4%) were not referred to care because 
of incarceration, relocation, or work requirements 
for the substance abuse recovery program, and nine 
(4.6%) reported that they were already in care (Figure). 
More than half (123 of 241, 51.0%) people identified 
with chronic HCV infection from our testing sites 
attended an initial appointment for HCV care during 
the project period.
DISCUSSION
HCV testing and linkage to care can be facilitated at the 
local public health level, where these services can be 
integrated with HIV/STD programs and coordinated 
through existing networks with other providers. By 
implementing screening for anti-HCV with reflex RNA 
testing in a public STD clinic, county jail, community 
testing sites, and a homeless clinic, we identified a 
12.0% overall prevalence of chronic HCV infection. 
Targeted testing at a homeless clinic based on risk 
factors identified the highest percentage of chronic 
HCV infection (22.6%, 19/84) among people tested. 
Table 1. Prevalence of hepatitis C virus infection among at-risk individuals,a by testing site and test results, 
Durham County, North Carolina, December 2012 through February 2014
Testing facility
Number tested 
for HCV  
infection
Number testing 
anti-HCV positive/
HCV RNA positive 
(percent)b
Number testing 
anti-HCV positive/
HCV RNA negative 
(percent)b
Number testing  
anti-HCV negative  
(percent)b
Number with 
indeterminate  
anti-HCV result  
(percent)b
Total 2,004 241 (12.0) 85 (4.2) 1,676 (83.6) 2 (,0.1)
STD clinic 471 47 (10.0) 17 (3.6) 405 (86.0) 2 (0.4)
County jail 708 66 (9.3) 23 (3.3) 619 (87.4) 0 (0.0)
Community testing site 741 109 (14.7) 41 (5.5) 591 (79.8) 0 (0.0)
Homeless health-care clinic 84 19 (22.6) 4 (4.8) 61 (72.6) 0 (0.0)
aAt-risk individuals included current and past injection drug users, individuals with human immunodeficiency virus infection, and people born 
between 1945 and 1965 (i.e., baby boomers) (for one-time testing). Other risk factors included incarceration, long-term sexual exposure to an 
HCV-infected person, history of multiple sexual partners or STDs, and men who have sex with men.
bPercentages are row percentages.
HCV 5 hepatitis C virus
anti-HCV 5 hepatitis C virus antibody 
RNA 5 ribonucleic acid
STD 5 sexually transmitted disease
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Table 2. Characteristics of and risk factors for at-risk individuals tested for hepatitis C virus at testing sites in 
Durham County, North Carolina, December 2012 through February 2014a
Characteristic
Number tested 
for HCV  
(percent)c
Number testing  
anti-HCV 
positiveb 
(percent)c 
Number testing 
anti-HCV  
negative  
(percent)c
Total tested 2,004 (100.0) 326 (16.3) 1,678 (83.7)
Median age, in years (IQR) 37 (27–50) 48 (33–53) 35 (26–48)
Categorical age, in years    
  ,30 665 (33.2) 52 (16.0) 613 (36.5)
  30–49 824 (41.1) 127 (39.0) 697 (41.5)
  50–69 515 (25.7) 147 (45.1) 368 (21.9)
Birth cohort (1945–1965)    
  Yes 609 (30.4) 165 (50.6) 444 (26.5)
  No 1,395 (69.6) 161 (49.4) 1,234 (73.5)
Sex    
  Male 1,456 (72.7) 234 (71.8) 1,222 (72.8)
  Female 541 (27.0) 92 (28.2) 449 (26.8)
  Transgender 5 (0.2) 0 (0.0) 5 (0.3)
  Not reported 2 (0.1) 0 (0.0) 2 (0.1)
Race/ethnicity    
  Black 1,255 (62.6) 161 (49.4) 1,094 (65.2)
  White 542 (27.0) 147 (45.1) 395 (23.5)
  Hispanic 97 (4.8) 7 (2.2) 90 (5.4)
  Otherd 55 (2.7) 3 (0.9) 52 (3.1)
  Not reported 55 (2.7) 8 (2.5) 47 (2.8)
Country of birth    
  U.S.-born 1,821 (90.9) 305 (93.6) 1,516 (90.4)
  Foreign-born 86 (4.3) 4 (1.2) 82 (4.9)
  Not reported 97 (4.8) 17 (5.2) 80 (4.8)
Health insurance status    
  Yes 464 (23.2) 57 (17.5) 407 (24.3)
  No 1,349 (67.3) 233 (71.5) 1,116 (66.5)
  Not reported 191 (9.5) 36 (11.0) 155 (9.2)
  Type of health insurance (among those with insurance)    
    Public 242 (52.2) 36 (63.2) 206 (50.6)
    Private 141 (30.4) 13 (22.8) 128 (31.5)
    Other 1 (0.2) 0 (0.0) 1 (0.3)
    Not reported 80 (17.2) 8 (14.0) 72 (17.7)
Ever injected drugs    
  Yes 371 (18.5) 197 (60.4) 174 (10.4)
  No 1,445 (72.1) 97 (29.8) 1,348 (80.3)
  Not reported 188 (9.4) 32 (9.8) 156 (9.3)
  Injected drugs within the past 12 months (among those who ever injected)    
    Yes 178 (48.0) 90 (45.7) 88 (50.6)
    No 193 (52.0) 107 (54.3) 86 (49.4)
HIV status    
  HIV infection 37 (1.8) 8 (2.5) 29 (1.7)
  No HIV infection 1,452 (72.5) 250 (76.7) 1,202 (71.6)
  Not reported 515 (25.7) 68 (20.9) 447 (26.6)
aAt-risk individuals included current and past injection drug users, individuals with HIV, and people born between 1945 and 1965 (i.e., baby 
boomers) (for one-time testing). Other risk factors included incarceration, long-term sexual exposure to an HCV-infected person, history of 
multiple sexual partners or sexually transmitted diseases (STDs), and men who have sex with men. Testing sites included an STD clinic, county 
jail, homeless health-care clinic, and community testing sites.
bThe anti-HCV-positive group included people who were anti-HCV positive/ribonucleic acid (RNA) positive or antibody positive/RNA negative.
cPercentages may not total to 100 because of rounding.
dOther race includes multiracial, Asian, American Indian/Alaska Native, and Native Hawaiian/Pacific Islander.
HCV 5 hepatitis C virus
anti-HCV 5 hepatitis C virus antibody
IQR 5 interquartile range
HIV 5 human immunodeficiency virus
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However, linkage to HCV care was challenging for a 
predominantly uninsured population, and necessitated 
the assistance of a patient navigator and development 
of on-site HCV clinics to reduce barriers for people 
with chronic HCV infection. 
Since 1998, CDC has recommended HCV screening 
based on risk factors such as intravenous drug use, 
HIV infection, and other medical conditions.17 Unfor-
tunately, barriers remain for IDUs, who typically have 
limited access to HCV care outside of drug treatment 
facilities.18 As such, targeted HCV screening in STD 
clinics and other public health venues is a reasonable 
strategy for reaching IDUs and other at-risk individuals. 
An earlier study by Hennessy et al. reported integrated 
HCV testing among patients attending a New York City 
STD clinic. Although only 3% of patients reported 
intravenous drug use in the study, the authors noted 
that hepatitis services attracted at-risk IDUs to the 
clinic, which increased the use of additional HIV/
STD services by this population.19 Jewett et al. recently 
demonstrated the feasibility of integrating HCV point-
of-care testing to patients with at least one risk factor in 
a Denver, Colorado, STD clinic.20 In clinics providing 
health care for the homeless, Strehlow et al. identified 
a 31% prevalence of anti-HCV positivity among home-
less adults with a history of intravenous drug use or 
prior incarceration.21 
Similar to the HIV care cascade,22,23 an HCV cas-
cade of care with decreasing proportions of infected 
people knowing their status, being engaged in care, 
and achieving virological response exists.24,25 We were 
able to increase the proportion of people in the initial 
steps of the cascade by using strategies such as patient 
navigation and HCV clinics colocated at the testing 
sites. A randomized trial conducted by Masson et al. 
involving HCV care coordination, on-site screening, 
and motivational enhanced education at metha-
done clinics found that their intervention increased 
 adherence to hepatitis A/B vaccinations and HCV 
evaluations. In their study, case managers coordinated 
aAt-risk detainees included current and past injection drug users, people with human immunodeficiency virus infection, and people born 
between 1945 and 1965 (i.e., baby boomers) (for one-time testing). Other risk factors included incarceration, long-term sexual exposure to an 
HCV-infected person, history of multiple sexual partners or sexually transmitted diseases (STDs), and men who have sex with men. Testing sites 
included an STD clinic, county jail, homeless health-care clinic, and community testing sites.
bReasons for not being referred for HCV care included incarceration (n521), relocation (n51), work requirements of the residential drug 
treatment recovery program (n52), and no specified reason (n530).
HCV 5 hepatitis C virus
Figure. At-risk detainees identified with chronic active hepatitis C virus infection and the proportion linked to 
care at testing sites in Durham County, North Carolina, December 2012 through February 2014a
Received HCV results  
and posttest counseling:  
197 (81.7%)
People with chronic  
active HCV infection: 241
Referred to HCV care:  
134 (68.0%)
Not referred to HCV care:  
54 (27.4%)
Reported already in care:  
9 (4.6%)
Did not receive HCV  
results and posttest 
counseling: 44 (18.3%)
Attended first  
appointment:  
123 (91.8%)
Did not attend  
first appointment:  
11 (8.2%)
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HCV evaluation  appointments with primary care and 
hepatology clinics located near methadone clinics in 
San Francisco, California, and New York City.26 
In our program, we initiated on-site HCV clinics at 
the substance abuse recovery program and the health 
department after several patients missed or failed to 
attend their appointments at the academic hospitals. 
The HCV providers at these on-site clinics conducted 
HCV-focused histories, examinations, and general 
assessments for liver decompensation, and provided 
counseling on HCV treatment, potential side effects, 
and outcomes.27 Our health-care providers comprised 
liver and infectious disease specialists who volun-
teered their time to provide initial HCV assessments; 
additionally, they had the ability to refer patients 
needing complex evaluations or treatment to their 
own specialty clinics at the academic centers. Other 
successful integrated models of HCV care delivery 
have been reported, including partnering of primary 
care clinics with HCV specialists, telemedicine, and 
distance-learning programs in which specialty care can 
be extended to increase access to HCV care.28,29 These 
models are attractive in that HCV-infected patients can 
potentially be linked to a primary medical home, where 
they can be followed until they require direct-acting 
antiviral therapies or other HCV treatment regimens 
that can be comanaged with HCV specialists. 
We learned several lessons during the linkage-to-care 
process that may benefit other jurisdictions seeking 
to implement a similar program. First, engaging and 
connecting with a network of health-care providers 
who can offer HCV care was critical to support testing 
activities. Second, scheduling medical appointments 
within a month of the bridging session followed by 
frequent reminders led to a greater likelihood that 
patients would attend their first appointment. We 
found that the completeness of contact information 
obtained during HCV testing was crucial to minimizing 
loss to follow-up for posttest counseling and linkage to 
care. Lastly, we alleviated the transportation barrier for 
our population by providing on-site HCV clinics with 
health-care providers. 
Limitations
Our project was subject to several limitations. First, we 
lacked data regarding subsequent steps in the HCV care 
cascade (e.g., retention in care, completion of therapy, 
and sustained virological response). Second, the project 
goals were predominantly focused on increasing the 
number of individuals who were aware of their HCV 
status and linked to care. A small proportion of people 
whom we tested reported being aware of their anti-
HCV status or that they were already in care, but we 
lacked the resources to verify the information. Third, 
we deployed HCV specialists to provide care at on-site 
clinics, which may be difficult to implement in other 
jurisdictions. Lastly, we provided HCV screening and 
linkage-to-care activities at one local North Carolina 
health department; as such, our results may not be 
generalizable to other U.S. public health departments. 
CONCLUSION
In 2010, the Institute of Medicine indicated that the 
lack of knowledge and awareness about viral hepatitis 
and insufficient understanding about the extent of this 
public health problem impeded efforts to prevent and 
control HCV.30 Ward et al. also stated that lack of public 
and provider awareness has led to inadequate public 
health and health-care resource allocation for HCV.31 
Additionally, challenges for individuals with chronic 
HCV infection, including no health insurance, lack of 
transportation, and access to HCV care, prevail. At the 
local public health level, we demonstrated that HCV 
testing and linkage to care can be facilitated with the 
support of federal funds and by leveraging existing 
HIV/STD programs and provider networks to deliver 
a coordinated system of care. 
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